Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gastroparesis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Gastroparesis. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-003279-38 Sponsor Protocol Number: TZP-101-CL-G004 Start Date*: 2007-08-17
    Sponsor Name:Tranzyme Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of TZP-101 when Administered as a 30 Minute I.V. Infusion to Subjects with Severe G...
    Medical condition: TZP-101 will be developed as a first-in class therapy for the treatment of gastric dysmotility.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002254-86 Sponsor Protocol Number: NAT-19/GPX Start Date*: 2022-09-26
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomised, placebo-controlled, dose-finding phase IIb trial to evaluate the efficacy, safety, and tolerability of a 12-week-treatment with Naronapride in adult participants with at l...
    Medical condition: idiopathic or diabetic gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    20.1 10017947 - Gastrointestinal disorders 10021227 Idiopathic gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) PL (Ongoing) NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000308-16 Sponsor Protocol Number: prucalopride1 Start Date*: 2011-10-24
    Sponsor Name:UZ Leuven
    Full Title: Prucalopride versus Placebo in Idiopathic and Diabetic Gastroparesis
    Medical condition: Patients with delayed gastric emptying (t1/2 for solids ≥ 109 min) either from idiopathic or diabetic origin
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10021227 Idiopathic gastroparesis LLT
    14.0 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-007226-19 Sponsor Protocol Number: TZP-102-CL-G002 Start Date*: 2009-05-15
    Sponsor Name:Tranzyme Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP 102 for the Treatment of Symptomatic...
    Medical condition: The medical condition to be investigated is gastroparesis due to diabetes mellitus.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018043 Gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) GB (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002594-33 Sponsor Protocol Number: TZP-102-CL-G003 Start Date*: 2011-10-14
    Sponsor Name:Tranzyme, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of Once-Daily Administrations of TZP 102 for the Treatment of Symptoms Associated w...
    Medical condition: The medical condition to be investigated is symptomatic gastroparesis due to diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10018043 Gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DK (Completed) DE (Completed) BE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001275-21 Sponsor Protocol Number: TAK-906-2002 Start Date*: 2019-06-18
    Sponsor Name:Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally Acting Dopamine ...
    Medical condition: Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10018043 Gastroparesis LLT
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    20.1 10017947 - Gastrointestinal disorders 10021227 Idiopathic gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002576-14 Sponsor Protocol Number: TZP-102-CL-G004 Start Date*: 2012-08-23
    Sponsor Name:Tranzyme, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associate...
    Medical condition: The medical condition to be investigated is symptomatic gastroparesis due to diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004856 10018043 Gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-004997-23 Sponsor Protocol Number: M0003-C201 Start Date*: 2007-11-23
    Sponsor Name:Movetis NV
    Full Title: An exploratory, double-blind, randomized, stratified, placebo-controlled, repeated dose trial to investigate the efficacy of M0003 on symptoms suggestive for gastroparesis, to assess the pharmacody...
    Medical condition: Symptoms suggestive for gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018043 Gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) LT (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005489-46 Sponsor Protocol Number: OPEGG Start Date*: 2016-02-02
    Sponsor Name:Umeå University
    Full Title: Recovery of gastric function after treatment with shortacting opioids.
    Medical condition: The effect of opioids on gastric electrical activity
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004856 10018043 Gastroparesis LLT
    18.1 10022117 - Injury, poisoning and procedural complications 10018044 Gastroparesis postoperative PT
    18.1 100000004856 10021227 Idiopathic gastroparesis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023186-21 Sponsor Protocol Number: MOT114479 Start Date*: 2011-06-28
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist ...
    Medical condition: Diabetic gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003250-13 Sponsor Protocol Number: 0099 Start Date*: 2015-05-06
    Sponsor Name:Theravance Biopharma R&D, Inc.
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic ...
    Medical condition: diabetic or idiopathic gastroparesis.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10017947 - Gastrointestinal disorders 10021227 Idiopathic gastroparesis LLT
    17.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-008175-34 Sponsor Protocol Number: MOT111809 Start Date*: 2009-03-31
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Multicenter, Double-Blind, Randomized Placebo-Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Single Doses of the Oral Motilin Receptor A...
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051153 Diabetic gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000867-18 Sponsor Protocol Number: Codeine_I Start Date*: 2016-03-25
    Sponsor Name:KU Leuven
    Full Title: THE EFFECT OF CODEINE ON GASTRIC MOTILITY AS MEASURED WITH AN INTRAGASTRIC BALLOON
    Medical condition: gastroparesis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002143-15 Sponsor Protocol Number: RLM-MD-03 Start Date*: 2018-11-06
    Sponsor Name:Allergan Ltd.
    Full Title: A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) LV (Prematurely Ended) HU (Completed) FR (Completed) BE (Completed) DK (Prematurely Ended) BG (Completed) AT (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000406-30 Sponsor Protocol Number: 3071-305-020 Start Date*: 2020-07-13
    Sponsor Name:Allergan Limited
    Full Title: Open-label Extension Study of Relamorelin for the Treatment of Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-010547-13 Sponsor Protocol Number: Amisulpiride01 Start Date*: 2010-09-16
    Sponsor Name:UZLeuven
    Full Title: Amisulpride versus Placebo in Functional Dyspespia with delayed gastric emptying
    Medical condition: delayed gastric emptying
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012199 Delayed gastric emptying LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005623-27 Sponsor Protocol Number: RM-131-009 Start Date*: 2015-04-08
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients with Vomiting Symptoms and Moderate to Severe Diabetic Gastropa...
    Medical condition: Vomiting symptoms in patient with moderate to severe diabetic gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002136-16 Sponsor Protocol Number: RLM-MD-01 Start Date*: 2019-04-02
    Sponsor Name:Allergan Ltd.
    Full Title: A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004217-42 Sponsor Protocol Number: 0001 Start Date*: 2005-04-26
    Sponsor Name:AKH Wien
    Full Title: Injektion von Botulinum Toxin in den Pylorus zur Behandlung von Chronic Upper Gastrointestinal Symptoms bei Diabetic Patients mit verzögerter Gastric Emptying
    Medical condition: Diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002177-20 Sponsor Protocol Number: RLM-MD-02 Start Date*: 2018-11-06
    Sponsor Name:Allergan Ltd.
    Full Title: A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) LV (Prematurely Ended) HU (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Prematurely Ended) AT (Completed) RO (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Apr 28 06:41:31 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA